This Phase 3 study tests an investigational injectable medication for cirrhosis caused by MASH (formerly NASH). Participants receive weekly doses of the medication or a placebo for up to 4.5 years to evaluate its impact on liver-related clinical outcomes.

Offer convert on one page form submit, users can click "see if you qualify" to access the submission form.

Targeting: The study is restricted to specific locations found here: Live Geos Report. The audience includes adults aged 18+ who have been told by a doctor they may have cirrhosis of the liver.

Restrictions: No incent, Meta Instant Forms (Instaforms) or brand bidding traffic, Participants must consume no more than 10 alcoholic beverages per week and must not have had weight loss surgery within the past five years. All copy and creatives must be approved